A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability. Bioorg Med Chem Lett

Medicinal Chemistry Group, Institut Pasteur Korea, Sampyeong-dong 696, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.42). 02/2012; 22(7):2522-6. DOI: 10.1016/j.bmcl.2012.01.133
Source: PubMed

ABSTRACT Following the previous SAR of a novel dihydropyrimidinone scaffold as HIV-1 replication inhibitors a detailed study directed towards optimizing the metabolic stability of the ester functional group in the dihydropyrimidinone (DHPM) scaffold is described. Replacement of the ester moiety by thiazole ring significantly improved the metabolic stability while retaining antiviral activity against HIV-1 replication. These novel and potent DHPMs with bioisosteres could serve as advanced leads for further optimization.

Download full-text


Available from: Sung-Jun Han, Aug 05, 2014
1 Follower
35 Reads
  • Source
    • "Recently, an appropriately functionalized dihydropyrimidine analogue of novel 4-aryl-5-isopropoxy- carbonyl-6-methyl-3,4-dihydropyrimidinones emerged as an anti-microbiological agent [5]. A novel 3,4- dihydropyrimidin-2(1H)-one was reported to inhibit HIV-1 replication with improved metabolic stability [6], and its special structure was found to occur naturally in marine alkaloid batzelladines; these are the first "
    [Show abstract] [Hide abstract]
    ABSTRACT: A facile synthesis of 3,4-dihydropyrimidin-2(1H)-ones/-thiones (DHPMs) through Biginelli reaction by the condensation reaction of aldehydes, β-ketoesters and urea/thiourea employing p-dodecylbenzenesulfonic acid (DBSA) as a recyclable catalyst under solvent-free condition at 80 °C is described. Furthermore, a series of indeno[1,2-d]pyrimidines have also been synthesized using the same conditions by the Biginelli-like reaction of 2H-indene-1,3-dione, with urea/thiourea and aromatic aldehyde. All the products in both reactions obtained in good to excellent yields by proceeding through a simple and efficient procedure. All the synthesized compounds structure has been established by advanced spectroscopic data
    07/2014; 8(3). DOI:10.1016/j.jtusci.2014.03.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: The application of bioisosteres in drug discovery is a well-established design concept that has demonstrated utility as an approach to solving a range of problems that affect candidate optimization, progression, and durability. In this chapter, the application of isosteric substitution is explored in a fashion that focuses on the development of practical solutions to problems that are encountered in typical optimization campaigns. The role of bioisosteres to affect intrinsic potency and selectivity, influence conformation, solve problems associated with drug developability, including P-glycoprotein recognition, modulating basicity, solubility, and lipophilicity, and to address issues associated with metabolism and toxicity is used as the underlying theme to capture a spectrum of creative applications of structural emulation in the design of drug candidates.
    Tactics in Contemporary Drug Design, 01/2013: pages 283-381;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: There is a continuous need for next-generation non-nucleoside RT inhibitors (NNRTIs) with different resistance profiles, improved safety, excellent tolerability, and favorable physicochemical properties. Areas covered: In this review we intend to narrate a general and cutting-edge overview of current state of NNRTI patents during the 2011-2014 (June) period and future perspectives. Particular focus is placed on the highlighting of some emerging medicinal chemistry principles and insights in the discovery and development of NNRTIs. Expert opinion: The development of effective NNRTIs is moving on from trial-and-error approaches to sophisticated subconscious strategies. Several newly emerging structure-based virtual screening methodologies (such as Monte Carlo free energy perturbation calculations) or new drug design insights, such as taking full use of the specific noncovalent reverse transcriptase/NNRTIs interactions, stereochemical diversity-oriented conformational restriction, novel strategies to enhance solubility and early absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment, will continue to evolve to complement the classical NNRTIs discovery approaches (structure-based core-refining and substituents-decorating).
    Expert Opinion on Therapeutic Patents 10/2014; 24(11). DOI:10.1517/13543776.2014.964685 · 4.30 Impact Factor
Show more